The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 8, 2014, Pages 981-992

  Gonçalves, Inês C ^a,b   Henriques, Patrícia C ^a,b   Seabra, Catarina L ^a,b   Martins, M Cristina L ^a,b  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

biomaterials; chitosan; crosslinking; drug delivery; gastric cancer; Helicobacter pylori; microspheres; mucoadhesion; nanoparticles; polyelectrolytes

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CHITOSAN; CLARITHROMYCIN; FUCOSE; METRONIDAZOLE; NANOPARTICLE; OMEPRAZOLE; TETRACYCLINE; ANTIINFECTIVE AGENT; DRUG CARRIER;

ANTIMICROBIAL ACTIVITY; BACTERIAL CLEARANCE; BACTERIAL STRAIN; CHEMICAL STRUCTURE; DRUG COATING; DRUG DELIVERY SYSTEM; GASTRIC INFECTION; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PH; REVIEW; ADHESION; CHEMISTRY; COMPLICATION; DRUG EFFECTS; DRUG FORMULATION; GASTRITIS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTIC ULCER; STOMACH MUCOSA; STOMACH NEOPLASMS;

ADHESIVENESS; ANTI-BACTERIAL AGENTS; CHITOSAN; DRUG CARRIERS; DRUG COMPOUNDING; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NANOPARTICLES; PEPTIC ULCER; STOMACH NEOPLASMS;

EID: 84904003586     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.930663     Document Type: Review

References (79)

1. Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;23(4):713-39
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in. 2008;Eur J Cancer 2010; 46(4):765-81
3. Stewart BW, Kleihues P. World cancer report. International Agency for Research on Cancer; Lyon, France: 2003. p. 351
4. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infectio- the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64
5. Allen A, Cunliffe WJ, Pearson JP, Venables CW. The adherent gastric mucus gel barrier in man and changes in peptic ulceration. J Intern Med Suppl 1990;732: 83-90
6. Celli JP, Turner BS, Afdhal NH, et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci USA 2009;106(34):14321-6
7. Dubois A, Boren T. Helicobacter pylori is invasive and it may be a facultative intracellular organism. Cell Microbiol 2007; 9(5):1108-16
8. Kobayashi M, Lee H, Nakayama J, Fukuda M. Carbohydrate-dependent defense mechanisms against Helicobacter pylori infection. Curr Drug Metab 2009;10(1): 29-40
9. Evans DJ Jr, Evans DG. Helicobacter pylori adhesins: review and perspectives. Helicobacter 2000;5(4):183-95
10. Aspholm M, Kalia A, Ruhl S, et al. Helicobacter pylori adhesion to carbohydrates. Methods Enzymol 2006;417: 293-339
11. Namavar F, Sparrius M, Veerman EC, et al. Neutrophil-activating protein mediates adhesion of Helicobacter pylori to sulfated carbohydrates on high-molecular-weight salivary mucin. Infect Immun 1998;66(2): 444-7
12. Odenbreit S, Faller G, Haas R. Role of the alpAB proteins and lipopolysaccharide in adhesion of Helicobacter pylori to human gastric tissue. Int J Med Microbiol 2002; 292(3-4):247-56
13. Dossumbekova A, Prinz C, Mages J, et al. Helicobacter pylori HopH (OipA) and bacterial pathogenicity: genetic and functional genomic analysis of hopH gene polymorphisms. J Infect Dis 2006;194(10): 1346-55
14. Kwok T, Zabler D, Urman S, et al. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature 2007;449(7164):862-6
15. Vakil N. Helicobacter pylori treatment: a practical approach. Am J Gastroenterol 2006;101(3):497-9
16. Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev Vaccines 2009;8(8):1037-49
17. Parreira P, Fátima Duarte M, Reis CA, Martins MC. Helicobacter pylori infection: a brief overview on alternative natural treatments to conventional therapy. Crit Rev Microbiol 2014. [Epub ahead of print]
18. Makobongo MO, Gilbreath JJ, Merrell DS. Nontraditional therapies to treat Helicobacter pylori infection. J microbiol 2014;52(4):259-72
19. Correia M, Michel V, Matos AA, et al. Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization. PLoS One 2012;7(4): e35072
20. Adebisi A, Conway BR. Gastroretentive microparticles for drug delivery applications. J Microencapsul 2011;28(8):689-708
21. Arora S, Bisen G, Budhiraja RD. Mucoadhesive and muco-penetrating delivery systems for eradication of Helicobacter pylori. Asian J Pharm 2012;6: 18-30
22. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010; 9(8):615-27
23. Gonçalves IC, Magalhaes A, Fernandes M, et al. Bacterial-binding chitosan microspheres for gastric infection treatment and prevention. Acta Biomater 2013;9(12): 9370-8
24. Xie Y, Zhou NJ, Gong YF, et al. Th immune response induced by H. pylori vaccine with chitosan as adjuvant and its relation to immune protection. World J Gastroenterol 2007;13(10):1547-53
25. Dash M, Chiellini F, Ottenbrite RM, Chiellini E. Chitosan - A versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci 2011;36(8): 981-1014
26. Kato Y, Onishi H, Machida Y. Application of chitin and chitosan derivatives in the pharmaceutical field. Curr Pharm Biotechnol 2003;4(5):303-9
27. Mi FL, Sung HW, Shyu SS, et al. Synthesis and characterization of biodegradable TPP/ genipin co-crosslinked chitosan gel beads. Polymer (Guildf) 2003;44(21):6521-30
28. Mi FL, Sung HW, Shyu SS. Synthesis and characterization of a novel chitosan-based network prepared using naturally occurring crosslinker. J Polym Sci 2000;38(15): 2804-14
29. Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacromolecules 2008;9(7):1837-42
30. Strand SP, Vandvik MS, Varum KM, Ostgaard K. Screening of chitosans and conditions for bacterial flocculation. Biomacromolecules 2001;2(1):126-33
31. Luo D, Guo J, Wang F, et al. Preparation and evaluation of anti-Helicobacter pylori efficacy of chitosan nanoparticles in vitro and in vivo. J Biomater Sci Polym Ed 2009; 20(11):1587-96
32. Ramteke S, Ganesh N, Bhattacharya S, Jain NK. Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori. J Drug Target 2009;17(3):225-34
33. Crini G, Badot PM. Application of chitosan, a natural aminopolysaccharide, for dye removal from aqueous solutions by adsorption processes using batch studies: a review of recent literature. Prog Polym Sci 2008;33(4):399-447
34. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70(1-2): 1-20
35. Conway BR. Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr Pharm Des 2005;11(6):775-90
36. Lin YH, Chang CH, Wu YS, et al. Development of pH-responsive chitosan/ heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials 2009;30(19):3332-42
37. Huang YC, Chiang CH, Yeh MK. Optimizing formulation factors in preparing chitosan microparticles by spray-drying method. J Microencapsul 2003;20(2): 247-60
38. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004; 100(1):5-28
39. Patel JK, Patel MM. Stomach Specific Anti-Helicobacter pylori Therapy: Preparation and Evaluation of Amoxicillin-Loaded Chitosan Mucoadhesive Microspheres. Curr Drug Deliv 2007;4(1): 41-50
40. Hejazi R, Amiji M. Stomach-specific anti- H. pylori therapy. I: preparation and characterization of tetracyline-loaded chitosan microspheres. Int J Pharm 2002; 235(1-2):87-94
41. Fernandes M, Goncalves IC, Nardecchia S, et al. Modulation of stability and mucoadhesive properties of chitosan microspheres for therapeutic gastric application. Int J Pharm 2013;454(1): 116-24
42. Dong Y, Ng WK, Shen S, et al. Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers. Carbohydr Polym 2013;94(2):940-5
43. Sung HW, Huang RN, Huang LL, et al. Feasibility study of a natural crosslinking reagent for biological tissue fixation. J Biomed Mater Res 1998;42(4):560-7
44. Mi FL, Sung HW, Shyu SS. Release of indomethacin from a novel chitosan microsphere prepared by a naturally occurring crosslinker: examination of crosslinking and polycation-anionic drug interaction. J Appl Polym Sci 2001;81(7): 1700-11
45. Mi FL, Shyu SS, Peng CK. Characterization of ring-opening polymerization of genipin and pH-dependent cross-linking reactions between chitosan and genipin. J Polym Sci 2005;43(10):1985-2000
46. Zhu X, Zhou D, Guan S, et al. Preparation and characterization of novel multi-core chitosan microspheres for stomach-specific delivery of hydrophilic antibiotics. J Mater Sci Mater Med 2012;23(4):983-90
47. Patel J, Patil P. Preparation and characterization of amoxicillin mucoadhesive microparticles using solution-enhanced dispersion by supercritical CO2. J Microencapsul 2012;29(4):398-408
48. Jain SK, Jangdey MS. Lectin conjugated gastroretentive multiparticulate delivery system of clarithromycin for the effective treatment of Helicobacter pylori. Mol Pharm 2009;6(1):295-304
49. Bhattarai R, Dhandapani N, Shrestha A. Drug delivery using alginate and chitosan beads: an overview. Chron Young Sci 2011; 2(4):192-6
50. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci 2012;37(1):106-26
51. Antunes JC, Pereira CL, Molinos M, et al. Layer-by-layer self-assembly of chitosan and poly(gamma-glutamic acid) into polyelectrolyte complexes. Biomacromolecules 2011;12(12):4183-95
52. Gonçalves RM, Antunes JC, Barbosa MA. Mesenchymal stem cell recruitment by stromal derived factor-1-delivery systems based on chitosan/poly(gamma-glutamic acid) polyelectrolyte complexes. Eur Cell Mater 2012;23:249-60.discussion 260-241
53. Berger J, Reist M, Mayer JM, et al. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm 2004;57(1):35-52
54. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev 2010;62(1):83-99
55. Hamman JH. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Mar Drugs 2010;8(4):1305-22
56. Thamphiwatana S, Fu V, Zhu J, et al. Nanoparticle-stabilized liposomes for pH-responsive gastric drug delivery. Langmuir 2013;29(39):12228-33
57. Angadi SC, Manjeshwar LS, Aminabhavi TM. Novel composite blend microbeads of sodium alginate coated with chitosan for controlled release of amoxicillin. Int J Biol Macromol 2012; 51(1-2):45-55
58. Nogueira F, Goncalves IC, Martins MC. Effect of gastric environment on Helicobacter pylori adhesion to a mucoadhesive polymer. Acta Biomater 2013;9(2):5208-15
59. Parreira P, Magalhães A, Reis CA, et al. Bioengineered surfaces promote specific protein-glycan mediated binding of the gastric pathogen Helicobacter pylori. Acta Biomaterialia 2013;9:11:8885-93
60. Martins MCL, Goncalves IC, Gomes P, et al. Microspheres. WO2013164652. 2013
61. Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Dis 2013;12(5):371-87
62. Jakobsson HE, Jernberg C, Andersson AF, et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. Plos One 2010; 5(3):e9836
63. Sarmento B, das Neves J. Chitosan-based systems for biopharmaceuticals: delivery, targeting and polymer therapeutics. John Wiley & Sons Ltd; UK: 2012
64. Ma L, Liu C. Preparation of chitosan microspheres by ionotropic gelation under a high voltage electrostatic field for protein delivery. Colloids surf B Biointerfaces 2010; 75(2):448-53
65. Mao HQ, Roy K, Troung-Le VL, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 2001;70(3):399-421
66. Berthold A, Cremer K, Kreuter J. Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs. J Control Release 1996;39(1):17-25
67. He P, Davis SS, Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm 1998;166(1): 75-88
68. Torres MA, Vieira RS, Beppu MM, et al. Production of chemically modified chitosan microspheres by a spraying and coagulation method. Mater Res 2007;10:347-52
69. Roy S, Panpalia SG, Nandy BC, et al. Effect of Method of Preparation on Chitosan Microspheres of Mefenamic Acid. Int J Pharm Sci Drug Res 2009;1(1):36-42
70. Akbuga J, Durmaz G. Preparation and evaluation of cross-linked chitosan microspheres containing furosemide. Int J Pharm 1994;111(3):217-22
71. Mi FL, Tan YC, Liang HC, et al. In vitro evaluation of a chitosan membrane cross-linked with genipin. J Biomater Sci Polym Ed 2001;12(8):835-50
72. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001;74(1-3):317-23
73. Arora S, Gupta S, Narang RK, Budhiraja RD. Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. pylori. Sci Pharm 2011;79(3): 673-94
74. Arora S, Budhiraja RD. Chitosan-alginate microcapsules of amoxicillin for gastric stability and mucoadhesion. J Adv Pharm Technol Res 2012;3(1):68-74
75. Lin YH, Chiou SF, Lai CH, et al. Formulation and evaluation of water-in-oil amoxicillin-loaded nanoemulsions using for Helicobacter pylori eradication. Process Biochem 2012;47(10):1469-78
76. Lin YH, Tsai SC, Lai CH, et al. Genipin-cross-linked fucose-chitosan/ heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials 2013; 34(18):4466-79
77. Chang CH, Huang WY, Lai CH, et al. Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori. Acta Biomater 2011; 7(2):593-603
78. Chang CH, Lin YH, Yeh CL, et al. Nanoparticles incorporated in pH-sensitive hydrogels as amoxicillin delivery for eradication of Helicobacter pylori. Biomacromolecules 2010;11(1):133-42
79. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377(9769): 905-13 Tecnologia e a Tecnologia e a Tecnologia a Tecnologia e a Tecnologia Tecnologia Tecnologia